Schizophrenia.com
New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
News
everhopeful
April 7, 2022, 12:42pm
1
4 Likes
Related topics
Topic
Replies
Views
Activity
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
News
6
233
December 3, 2023
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
News
7
322
February 28, 2024
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
News
4
375
August 23, 2022
Minerva neurosciences reports update on roluperidone for treatment of negative symptoms of schizophrenia
News
5
726
September 6, 2022
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
News
4
324
May 1, 2023